Equity Field Notes from temporal sources

[DanWebzster]

MESO (update)

Q3/18 expecting 180-day follow-on data to Ph3 study that successfully met its primary endpoint

The expectation is to have the first industrial mfred allogenic mesenchymal lineage cell-based product in the U.S.

Although there is competition, it's very likely that there will be a niche for this GVHD treatment.

Cash runway now extends into Q4/19 and would likely get MESO thru a PDUFA decision.